Q-omics provides the consensus-scored WFDC10B profile across patient tissues and cancer cell-line models. WFDC10B expression is associated with patient survival in 22 of 34 cancer types, with the highest sampling consensus in KIRC. Among the 18 cancer types available for tumor–normal comparison, WFDC10B is differentially expressed in 15, with the highest sampling consensus in COAD. Additionally, WFDC10B RNA expression shows 10,463 significant protein co-abundance associations, with the highest sampling consensus in LUAD. Together, these results highlight KIRC, COAD, and LUAD as cancer lineages where WFDC10B shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for WFDC10B — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes WFDC10B survival associations across molecular data types. WFDC10B RNA expression shows survival associations in the most cancer types (22), followed by mutation status (3). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible WFDC10B RNA expression–survival associations across cancer types. High WFDC10B expression shows unfavorable associations in KIRC, KIRP, COAD, THCA and KICH, but favorable associations in LUAD. The KIRC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify KIRC as the clearest survival context for WFDC10B RNA expression.
This table summarizes WFDC10B tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 15. The strongest signals are observed in COAD for RNA.
This table ranks reproducible tumor–normal expression differences for WFDC10B. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. WFDC10B shows higher tumor expression in COAD, KIRC, PAAD, READ, BRCA and LUAD. The COAD box plot shows higher WFDC10B RNA expression in tumor versus normal tissue (log2 FC = +0.750, t-test p < 0.001).
This table shows molecular features associated with WFDC10B in patient tissues and cancer cell lines. In patient samples, WFDC10B shows the broadest associations at the RNA and protein expression levels, with LUAD recurring as the lineage with the largest associated feature set. In cancer cell lines, WFDC10B RNA and mutation anchors are most strongly linked to RNA-expression features, especially in SOFT_TISSUE, while CRISPR and shRNA rows add functional-dependency signals in UPPER_AERODIGESTIVE_TRACT and LUNG_NSCLC_LUAD.
